J&J’s Consumer Health Spinout Plan Surprises, But Seen As Sensible
Analysts say the pharma’s plan would separate out a unit with less growth and lower margins – and some predict a further breakup of the pharma and medical device units.
You may also be interested in...
Finance Watch: Sun Shines On Biotech Stocks As J.P. Morgan Ends
Public Company Edition: Also, Johnson & Johnson’s consumer health spin-out Kenvue filed paperwork to get the ball rolling on an initial public offering. In addition, Geron raised $198m and Madrigal accessed more than $300m after positive trial readouts, but layoffs were revealed by Editas, Elevation, Nabriva and others.
J&J, Flush With Cash, Has Flexibility To Be ‘Bolder’ On M&A, CEO Duato Says
The company kicked off the new year with a new CEO, plans to break out consumer health, and a strong financial position, including $32bn in cash and lowest level of net debt in more than four years.
J.P. Morgan Day 1: Pharma Execs Offer Big Talk Instead Of Big Deals
Daily notebook from the virtual J.P. Morgan Healthcare Conference: business development is top of mind for BMS, Merck, J&J and Pfizer, while Novartis, Moderna and Regeneron talk about next steps. Bayer looks to minimize Xarelto patent expiry, a new chief exec debuts for Alnylam and EY suggests 2022 will be another year of bolt-on deals.